Target Identification
Target Identification
批准号:
8519277
负责人:
MICHAEL NIEDERWEIS
金额:
$40.05万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
已结题
起止时间:
至 2015-07-31
关键词:
Biological AssayCell FractionationCell WallCell divisionCo-ImmunoprecipitationsDrug TargetingEscherichia coliEthambutolGene TargetingGenesGenus MycobacteriumGoalsGrowthHomologous GeneIn VitroLipid BilayersLiposomesMass Spectrum AnalysisMembraneMembrane ProteinsMethodsMusMycobacterium smegmatisMycobacterium tuberculosisNutrientPeptide HydrolasesPermeabilityPharmaceutical PreparationsPharmacologic SubstancePhysiologicalPost-Translational Protein ProcessingProtein Export PathwayProtein FragmentProteinsRecombinant ProteinsResearch PersonnelRifampinSiteSurface Plasmon ResonanceSwellingTetracyclinesVirulencecrosslinkinhibitor/antagonistisoniazidlink proteinlipid biosynthesismutantmycobacterialnovelprogramspromoterprotein complexresearch studyscreeningsolid state nuclear magnetic resonancesolutetuberculosis drugs
中文摘要
超过60%的药物靶点是膜蛋白。然而,目前只有一种抗结核药物
药物乙胺丁醇针对结核分枝杆菌的膜蛋白,表明这种巨大的潜力在很大程度上是
未发现结核分枝杆菌。新近发现的一种针对三磷酸腺苷的二芳基喹啉类药物
结核分枝杆菌合酶活性超过两种主要抗结核药物异烟肼和利福平
提供了这一假设正确的原则证据。因此,我们从以下项目中选择了11个
大约800种推定的结核分枝杆菌内膜蛋白,它们是结核分枝杆菌生长所必需的。
在体外或在小鼠体内的结核病。这些蛋白质被选择来涵盖广泛的功能,例如
基本营养物质的运输、细胞分裂、蛋白质和细胞壁的输出以及脂肪的生物合成。
此外,它们足够小,可以适用于当前的固态核磁共振方法。外型
膜蛋白提供了作为药物靶点的巨大优势,抑制剂可能不需要跨越这些靶点。
外膜是分枝杆菌极其有效的通透性屏障。此外,他们还
很可能代表新的药物靶点,因为它们似乎与其他
蛋白质。因此,我们在最初的靶点列表中包括了7个假定的外膜蛋白,其中6个
它们没有已知的功能。这个项目的目标是验证18个入选的
以膜蛋白为药物靶点,阐明这6种未知蛋白质的生理功能
并确定其中一些蛋白质可能的相互作用伙伴。
英文摘要
More than 60% of all drug targets are membrane proteins. However, only one of the current antituberculous
drugs, ethambutol, targets membrane proteins of M. tuberculosis indicating that this vast potential is largely
untapped for M. tuberculosis. The recent discovery of a new diarylquinoline drug that targets the ATP
synthase of M. tuberculosis and exceeds the activities of the two main TB drugs isoniazid and rifampin
provides proof of principle that this assumption is correct. Therefore, we have selected 11 out of
approximately 800 putative inner membrane proteins of M. tuberculosis, which are essential for growth of M.
tuberculosis in vitro or in mice. These proteins were selected to cover a broad variety of functions, such as
transport of essential nutrients, cell division, export of proteins and cell wall and lipid biosynthesis.
Furthermore, they are sufficiently small to be amenable to current solid-state NMR methods. Outer
membrane proteins offer the tremendous advantage as drug targets that inhibitors may not need to cross
the outer membrane which is an extremely efficient permeability barrier in mycobacteria. In addition, they
are likely to represent novel drug targets because they do not appear to show any similarity to other
proteins. Therefore, we included seven putative outer membrane proteins in our list of initial targets, six of
which have no known function. The goal of this project is to validate the potential of the 18 selected
membrane proteins as drug targets, to elucidate the physiological function of the 6 proteins with no known
homologs and to identify putative interaction partners for some of these proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Toxin secretion and trafficking by Mycobacterium tuberculosis
-
批准号:10632980
-
项目类别:
-
资助金额:$70.68万
-
财政年份:2023
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Siderophore secretion by Mycobacterium tuberculosis
-
批准号:10379326
-
项目类别:
-
资助金额:$19.25万
-
财政年份:2021
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Siderophore-dependent inhibitors of Mycobacterium tuberculosis
-
批准号:10199992
-
项目类别:
-
资助金额:$19.8万
-
财政年份:2020
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Siderophore-dependent inhibitors of Mycobacterium tuberculosis
-
批准号:10041925
-
项目类别:
-
资助金额:$24.73万
-
财政年份:2020
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Heme and hemoglobin utilization by Mycobacterium tuberculosis
-
批准号:10320404
-
项目类别:
-
资助金额:$64.91万
-
财政年份:2019
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Single-chain MspA for nanopore sequencing of DNA
-
批准号:9918943
-
项目类别:
-
资助金额:$18.56万
-
财政年份:2019
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Heme and hemoglobin utilization by Mycobacterium tuberculosis
-
批准号:10082420
-
项目类别:
-
资助金额:$65.05万
-
财政年份:2019
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Heme and hemoglobin utilization by Mycobacterium tuberculosis
-
批准号:10535449
-
项目类别:
-
资助金额:$57.86万
-
财政年份:2019
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
The necrosis-inducing toxin of Mycobacterium tuberculosis
-
批准号:9178625
-
项目类别:
-
资助金额:$53.42万
-
财政年份:2015
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Copper transport in Mycobacterium tuberculosis
-
批准号:8287161
-
项目类别:
-
资助金额:$35.9万
-
财政年份:2009
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Copper transport in Mycobacterium tuberculosis
-
批准号:8488399
-
项目类别:
-
资助金额:$33.74万
-
财政年份:2009
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Target Identification
-
批准号:7575455
-
项目类别:
-
资助金额:$42.16万
-
财政年份:2009
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Copper transport in Mycobacterium tuberculosis
-
批准号:7891369
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2009
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Copper transport in Mycobacterium tuberculosis
-
批准号:7697646
-
项目类别:
-
资助金额:$36.58万
-
财政年份:2009
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Copper transport in Mycobacterium tuberculosis
-
批准号:8092805
-
项目类别:
-
资助金额:$35.9万
-
财政年份:2009
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Porins of Mycobacterium tuberculosis
-
批准号:7012763
-
项目类别:
-
资助金额:$35.52万
-
财政年份:2005
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Porins of Mycobacterium tuberculosis
-
批准号:7173372
-
项目类别:
-
资助金额:$34.49万
-
财政年份:2005
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Porins of Mycobacterium tuberculosis
-
批准号:7347603
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2005
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Porins of Mycobacterium tuberculosis
-
批准号:6861360
-
项目类别:
-
资助金额:$36.21万
-
财政年份:2005
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
Porins of Mycobacterium tuberculosis
-
批准号:7559647
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2005
-
负责人:MICHAEL NIEDERWEIS
-
依托单位:
海外基金